Precigen PGEN is focused on building long-term growth visibility beyond its commercial-stage Papzimeos franchise through its AdenoVerse platform. While Papzimeos is currently driving the company’s revenue growth, the platform’s clinical progress could provide additional opportunities across multiple indications.
The company is developing PRGN-2009, an investigational AdenoVerse immunotherapy, in HPV-driven cancers.
The FDA recently granted platform technology designation to Precigen’s AdenoVerse immunotherapeutic platform. Management noted that the designation could benefit PRGN-2009 across multiple HPV-associated cancers, including cervical and oropharyngeal cancers, as well as future candidates targeting other cancers and diseases.
A multicenter phase II study is evaluating PRGN-2009 in combination with Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), in patients with recurrent or metastatic cervical cancer.
Merck’s biggest revenue driver, Keytruda, is approved for several types of cancers globally.
Precigen plans to provide an update on the broader AdenoVerse portfolio, including PRGN-2009, by the end of 2026. Management believes the success of Papzimeos and progress with PRGN-2009 reflect the platform's utility and support its long-term potential.
Though still in the early stages, it remains to be seen whether the potential expansion of the AdenoVerse platform could eventually complement Papzimeos and provide long-term growth visibility.
PGEN Banks on Papzimeos Commercial Uptake
Papzimeos is currently the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). The drug provides Precigen with a differentiated commercial position and a potentially durable revenue base.
Papzimeos has witnessed strong early commercial momentum since its approval and launch in 2025. In the first six months of 2026, the product generated $74.6 million in revenues. Importantly, product revenues from Papzimeos more than doubled sequentially during the second quarter of 2026.
Precigen is also pursuing additional growth opportunities outside the United States. A marketing authorization application, seeking approval for Papzimeos to treat adults with RRP, is currently under review in Europe.
A potential approval in Europe could further boost the drug’s sales and drive revenues.
Papzimeos also benefits from seven years of FDA market exclusivity through Aug. 14, 2032. Combined with its first-in-class position and lack of an approved competing therapy for adult RRP, this protection allows Precigen to establish a durable commercial franchise before potential competitors enter the market.
Inovio Pharmaceuticals INO is developing its lead candidate, INO-3107, a DNA-based immunotherapy as a treatment for RRP.
Inovio’s biologics license application for INO-3107 is currently under review in the United States, with a decision from the FDA expected on Oct. 30, 2026. INO remains focused on advancing the INO-3107 program toward a potential 2026 approval and commercialization.
PGEN’s Price Performance, Valuation and Estimates
Year to date, shares of Precigen have rallied 78% compared with the industry’s rise of 9.6%. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Precigen is trading at a premium to the industry. Going by the price/book ratio, the stock currently trades at 60.87 times trailing 12-month book value, higher than 4.02 times for the industry. The stock is also trading above its five-year mean of 4.28.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 bottom line has improved from a loss of 2 cents per share to earnings of 25 cents over the past 60 days. During the same time, earnings estimates for 2027 have increased from 25 cents per share to 86 cents during the same time.
Image Source: Zacks Investment Research
PGEN’s Zacks Rank
Precigen currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Precigen, Inc. (PGEN): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).